| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -31,643 | -66,761 |
| Stock-based compensation expense | 4,308 | 8,190 |
| Right-of-use asset - operating lease | -292 | -568 |
| Amortization (accretion) of premium (discount) on investment securities | 764 | 1,891 |
| Other non-cash items | -77 | -88 |
| Accounts receivable | 17,243 | NaN |
| Prepaid expenses and other assets | 4,525 | 8,581 |
| Accounts payable | 398 | -3,582 |
| Accrued expenses | 574 | 2,480 |
| Operating lease liabilities | -306 | -587 |
| Deferred revenue | 16,537 | NaN |
| Net cash used in operating activities | -32,295 | -70,076 |
| Purchases of short-term investments | 69,747 | 1,339,835 |
| Sales and maturities of short-term investments | 122,000 | 1,427,000 |
| Purchases of property and equipment | 0 | 590 |
| Net cash provided by (used in) investing activities | 52,253 | 86,575 |
| Proceeds from exercise of stock options and warrants | 3 | NaN |
| Net cash provided by financing activities | 3 | NaN |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 19,961 | 16,499 |
| Cash and cash equivalents at beginning of period | 59,820 | NaN |
| Cash and cash equivalents at end of period | 96,280 | NaN |
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)